• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    RADCOM, Lotus Technology And 3 Stocks To Watch Heading Into Monday

    4/8/24 3:19:46 AM ET
    $ACN
    $AGEN
    $BRAG
    $LOT
    Real Estate
    Real Estate
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACN alert in real time by email

    With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:

    Accenture plc (NYSE:ACN) agreed to acquire CLIMB to expand technology capabilities. Accenture shares climbed 0.3% to $333.99 in the after-hours trading session.

    Agenus Inc. (NASDAQ:AGEN) disclosed a 1-for-20 reverse stock split of common stock. Agenus shares fell 4.7% to $0.48 in after-hours trading.

    Lotus Technology Inc. (NASDAQ:LOT) is expected to report its unaudited fourth quarter financial results before the opening bell on April 8, 2024. Lotus Technology shares gained 0.6% to close at $6.76 on Friday.

    Check out our premarket coverage here

    RADCOM Ltd. (NASDAQ:RDCM) said that Mr. Guy Shemesh is stepping down from the role of CEO, effective April 7, 2024, due to personal reasons. The company’s board named Mr. Hilik Itman as interim CEO, effective April 7, 2024. RADCOM shares fell 2.4% to $10.52 in the after-hours trading session.

    Bragg Gaming Group Inc. (NASDAQ:BRAG) reported the resignation of its Chief Financial Officer Ronen Kannor. The company confirmed that it has started the search for a replacement CFO. Matevž Mazij, Chief Executive Officer and Chair of the Board said, "We thank Ronen for his dedication and commitment to Bragg over the past four years and for his unwavering service as a pivotal member of the leadership team." Bragg Gaming shares gained 1.1% to close at $ 6.60 on Friday.

     

    Check This Out: These 3 Tech And Telecom Stocks With Over 6% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts

    Get the next $ACN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACN
    $AGEN
    $BRAG
    $LOT

    CompanyDatePrice TargetRatingAnalyst
    Accenture plc
    $ACN
    1/22/2026$313.00Buy
    Berenberg
    Accenture plc
    $ACN
    1/6/2026$317.00Buy
    Truist
    Accenture plc
    $ACN
    12/16/2025$320.00Equal-Weight → Overweight
    Morgan Stanley
    Accenture plc
    $ACN
    10/23/2025$266.00Neutral
    Citigroup
    Accenture plc
    $ACN
    10/22/2025$251.00Equal Weight
    Wells Fargo
    Bragg Gaming Group Inc.
    $BRAG
    10/17/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Accenture plc
    $ACN
    9/3/2025$250.00Buy → Neutral
    Rothschild & Co Redburn
    Bragg Gaming Group Inc.
    $BRAG
    8/18/2025Buy → Hold
    The Benchmark Company
    More analyst ratings

    $ACN
    $AGEN
    $BRAG
    $LOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Accenture Appoints Rachel Frey Chief Communications Officer

    Accenture (NYSE:ACN) today announced the appointment of Rachel Frey as chief communications officer, a newly created role. Effective immediately, Frey reports to Accenture Chair and CEO Julie Sweet and joins Accenture's Global Management Committee. Frey brings more than two decades of experience in communications. In her most recent role as Accenture's global head of Corporate Communications, she strengthened the company's relationships with external audiences; developed and elevated an enhanced earned communications strategy that has strategically positioned Accenture and its leaders at the forefront of AI reinvention across every major sector and region around the world; and leveraged d

    2/11/26 10:43:00 AM ET
    $ACN
    Real Estate

    RADCOM Delivers 17.2% Full-Year Revenue Growth, Record Revenue and Operating Margins in 2025

    Sixth consecutive year of revenue growth, reflecting ongoing business momentum TEL AVIV, Israel, Feb. 11, 2026 /PRNewswire/ -- RADCOM Ltd. (NASDAQ:RDCM), a leader in next-generation AI-powered assurance solutions, announced today its financial results for the fourth quarter and full year ended December 31, 2025. "RADCOM delivered record revenue of $71.5 million and achieved its highest annual operating margins to date in 2025, marking six consecutive years of revenue growth," said Benny Eppstein, Chief Executive Officer of RADCOM. "We are scaling profitability, generating strong cash flow, and strengthening our balance sheet, reflecting a business model with clear operating leverage while d

    2/11/26 7:07:00 AM ET
    $RDCM
    Computer peripheral equipment
    Technology

    Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

    Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted for poster presentation at the American Association for Cancer Research- Immuno-Oncology (AACR-IO) Conference, taking place in Los Angeles, CA on February 18–21, 2026. The abstract, titled "Systemic and tumor-microenvironment inflammation shape outcomes in patients with immunologically cold, treatment-refractory tumors treated with Fc-enhanced anti–CTLA-4 botensilimab," evaluates how systemic inflammatory markers, tumor microenvironment (TME) immune activity, and peripheral immune cell states are

    2/9/26 1:00:00 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACN
    $AGEN
    $BRAG
    $LOT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Armen Garo H bought $324,050 worth of shares (500,000 units at $0.65) (SEC Form 4)

    4 - AGENUS INC (0001098972) (Issuer)

    2/15/24 6:59:48 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wiinberg Ulf bought $19,000 worth of shares (25,000 units at $0.76), increasing direct ownership by 25% to 124,063 units (SEC Form 4)

    4 - AGENUS INC (0001098972) (Issuer)

    11/17/23 4:22:11 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACN
    $AGEN
    $BRAG
    $LOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Berenberg initiated coverage on Accenture with a new price target

    Berenberg initiated coverage of Accenture with a rating of Buy and set a new price target of $313.00

    1/22/26 8:28:24 AM ET
    $ACN
    Real Estate

    Truist initiated coverage on Accenture with a new price target

    Truist initiated coverage of Accenture with a rating of Buy and set a new price target of $317.00

    1/6/26 8:54:10 AM ET
    $ACN
    Real Estate

    Accenture upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Accenture from Equal-Weight to Overweight and set a new price target of $320.00

    12/16/25 8:22:53 AM ET
    $ACN
    Real Estate

    $ACN
    $AGEN
    $BRAG
    $LOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chair and CEO Sweet Julie Spellman sold $1,461,102 worth of Class A ordinary shares (6,057 units at $241.23), decreasing direct ownership by 28% to 15,255 units (SEC Form 4)

    4 - Accenture plc (0001467373) (Issuer)

    2/10/26 5:07:10 PM ET
    $ACN
    Real Estate

    Director Uotani Masahiko covered exercise/tax liability with 300 units of Class A ordinary shares, decreasing direct ownership by 20% to 1,238 units (SEC Form 4)

    4 - Accenture plc (0001467373) (Issuer)

    2/10/26 9:02:10 AM ET
    $ACN
    Real Estate

    Director Travis Tracey Thomas covered exercise/tax liability with 313 units of Class A ordinary shares, decreasing direct ownership by 3% to 9,794 units (SEC Form 4)

    4 - Accenture plc (0001467373) (Issuer)

    2/10/26 9:02:00 AM ET
    $ACN
    Real Estate

    $ACN
    $AGEN
    $BRAG
    $LOT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Radcom Ltd.

    SCHEDULE 13G/A - RADCOM LTD (0001016838) (Subject)

    2/11/26 4:39:45 PM ET
    $RDCM
    Computer peripheral equipment
    Technology

    SEC Form 6-K filed by Radcom Ltd.

    6-K - RADCOM LTD (0001016838) (Filer)

    2/11/26 7:10:30 AM ET
    $RDCM
    Computer peripheral equipment
    Technology

    SEC Form S-8 filed by Accenture plc

    S-8 - Accenture plc (0001467373) (Filer)

    2/4/26 4:15:43 PM ET
    $ACN
    Real Estate

    $ACN
    $AGEN
    $BRAG
    $LOT
    Leadership Updates

    Live Leadership Updates

    View All

    Accenture Appoints Rachel Frey Chief Communications Officer

    Accenture (NYSE:ACN) today announced the appointment of Rachel Frey as chief communications officer, a newly created role. Effective immediately, Frey reports to Accenture Chair and CEO Julie Sweet and joins Accenture's Global Management Committee. Frey brings more than two decades of experience in communications. In her most recent role as Accenture's global head of Corporate Communications, she strengthened the company's relationships with external audiences; developed and elevated an enhanced earned communications strategy that has strategically positioned Accenture and its leaders at the forefront of AI reinvention across every major sector and region around the world; and leveraged d

    2/11/26 10:43:00 AM ET
    $ACN
    Real Estate

    LOTUS Appoints Piano Master Lang Lang as Friend of the Brand

    NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lotus Technology Inc. ("Lotus Tech" or the "Company") (NASDAQ:LOT), a leading global intelligent and luxury mobility provider, today updated that LOTUS announced world-renowned pianist Lang Lang as its Friend of the Brand, marking a new partnership built on a shared pursuit of precision, performance, and excellence. Recognized globally for his extraordinary technique and expressive artistry, Lang Lang has brought classical music to audiences across cultures and generations. His dedication to mastery through discipline and refinement closely mirrors LOTUS's engineering philosophy, where every detail is shaped to deliver pure driving performance.

    2/6/26 8:30:00 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

    Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassionnel (AAC) program. BOT is an Fc-enhanced multifunctional CTLA-4 antibody and BAL is a PD-1 antibody. In combination, BOT/BAL is being investigated in patients with microsatellite-stable colorectal cancer (MSS CRC), a population that has hi

    11/18/25 8:41:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACN
    $AGEN
    $BRAG
    $LOT
    Financials

    Live finance-specific insights

    View All

    RADCOM Delivers 17.2% Full-Year Revenue Growth, Record Revenue and Operating Margins in 2025

    Sixth consecutive year of revenue growth, reflecting ongoing business momentum TEL AVIV, Israel, Feb. 11, 2026 /PRNewswire/ -- RADCOM Ltd. (NASDAQ:RDCM), a leader in next-generation AI-powered assurance solutions, announced today its financial results for the fourth quarter and full year ended December 31, 2025. "RADCOM delivered record revenue of $71.5 million and achieved its highest annual operating margins to date in 2025, marking six consecutive years of revenue growth," said Benny Eppstein, Chief Executive Officer of RADCOM. "We are scaling profitability, generating strong cash flow, and strengthening our balance sheet, reflecting a business model with clear operating leverage while d

    2/11/26 7:07:00 AM ET
    $RDCM
    Computer peripheral equipment
    Technology

    RADCOM to Report Fourth Quarter and Full Year 2025 Results on Wednesday, February 11, 2026

    TEL AVIV, Israel, Jan. 27, 2026 /PRNewswire/ -- RADCOM Ltd. (NASDAQ:RDCM) announced today that it will report its financial results for the fourth quarter and full year, which ended December 31, 2025, on Wednesday, February 11, 2026, before the market opens on the Nasdaq Stock Market. RADCOM CEO Benny Eppstein and CFO Hod Cohen will hold a conference call and webinar on the same day at 8:00 AM Eastern Time (3:00 PM Israel Time) to review the financial results and answer questions from participants. Attendees can join the event by phone or audio webinar. Conference Call Access To join the conference call, please dial +1-866-652-8972 (US toll-free) or +972-3-918-0609 for other locations. Plea

    1/27/26 7:00:00 AM ET
    $RDCM
    Computer peripheral equipment
    Technology

    Accenture Reports First-Quarter Fiscal 2026 Results

    Accenture delivers strong new bookings and revenue growth at the top of the company's guided range, with strong profitability and free cash flow; Confirms outlook for fiscal 2026 revenue growth, and adjusted operating margin and EPS Accenture (NYSE:ACN) reported financial results for the first quarter of fiscal 2026 ended November 30, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218755982/en/ All comparisons are to the first quarter of fiscal 2025, unless noted otherwise. Accenture Chair and CEO Julie Sweet "I am very pleased with our $21 billion in new bookings, including 33 clients with quarterly bookings greater t

    12/18/25 6:39:00 AM ET
    $ACN
    Real Estate

    $ACN
    $AGEN
    $BRAG
    $LOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agenus Inc.

    SC 13G/A - AGENUS INC (0001098972) (Subject)

    11/14/24 7:58:18 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Agenus Inc.

    SC 13G/A - AGENUS INC (0001098972) (Subject)

    11/14/24 9:21:26 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Lotus Technology Inc.

    SC 13G - Lotus Technology Inc. (0001962746) (Subject)

    11/12/24 6:07:58 AM ET
    $LOT
    Auto Manufacturing
    Industrials